Oral Cancer Therapy Market Size
| Study Period | 2018-2028 |
| Market Size (2024) | USD 2.05 Billion |
| Market Size (2028) | USD 2.65 Billion |
| CAGR (2024 - 2028) | 5.32 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Oral Cancer Therapy Market Analysis
The Oral Cancer Therapy Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.65 billion by 2028, growing at a CAGR of 5.32% during the forecast period (2024-2028).
COVID-19 undoubtedly had a huge impact on the oral cancer market. The repercussions of the pandemic were mainly related to travel restrictions and the conversion of hospitals to COVID-19 centers, fear in the minds of the public, shortage of human resources, etc. To mitigate the reduction in the number of cases, many cancer hospitals have started services like telecommunication and telemedicine. For instance, according to the article published by the Asian Journal of Oral Health and Allied Sciences in January 2022, many telemedicine applications were launched during the pandemic for teleconsultation, such as Practo, Mfine, and TATA Health provide teleconsultation. Hence, these services have increased teleconsultation, which has shown a lucrative impact on market growth during the pandemic. Currently, COVID-19 has subsided, and services have their traction again in every country and this opportunity would be exploited to shape the oral cancer market.
Rising tobacco use and smoking habits, an increase in oral cancer patients with unmet needs, and a need for early treatment are driving the oral cancer market during the forecast period. The emergence and increasing usage of newer tobacco and nicotine products make tobacco use one of the major public health problems globally.
Tobacco use increases the risk of oral cancer and other oral-related diseases. For instance, a series of authoritative reports issued by the United States government and other various international health agencies have conclusively established that tobacco use, especially cigarette smoking, increases the burden of oral cancer patients. According to the American Lung Association, in May 2023, a burning cigarette produces more than 7000 chemicals, of which 69 are carcinogens. Hence, these carcinogens lead to oral cancer, and continued cigarette smoking is expected to have a significant impact on the market over the study period.
Furthermore, the new research studies on various treatments for oral cancers are expected to have a significant impact on the market growth. For instance, in May 2023, Janssen Pharmaceutical performed an open-label phase 2 study to assess the safety and effectiveness of enzalutamide in combination with a gonadotropin-releasing hormone agonist in subjects with salivary gland carcinoma that expresses the androgen receptor and is locally advanced metastatic. Similarly, in September 2023, researchers at New York University developed ORAI1 fuels for oral cancers that may provide promising therapeutic. Targeting this protein could provide a new approach to treating oral cancer, which causes persistent pain that worsens as it progresses. Hence, such developments increase the availability of new drugs in the market over the coming years, thereby projecting market growth over the forecast period.
However, a lack of awareness and the adverse effects of treatments for oral cancer impede the growth of the oral cancer market over the forecast period.
Oral Cancer Therapy Market Trends
Targeted Drug Therapy Segment is Expected to Witness Significant Growth Over the Forecast Period
Targeted therapy highlights the treatment modalities of cancer at the molecular level. These therapies are extremely targeted and specific. Targeted therapies have dramatically changed the landscape of treatments for a variety of oral cancers and improved clinical outcomes. Unlike conventional cancer treatment regimens, new agents interfere with the growth and survival of cancer cells by interacting with the specific receptors and intracellular signaling pathways involved in carcinogenesis and cancer progression.
For instance, in July 2023, Rakuten Medical, Inc., suggested that the novel treatment approach of Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy showed promising early results in patients with locoregional and metastatic head and neck squamous cell carcinoma (HNSCC). Additionally, targeted therapies are more advantageous because of their targeted actions; these drugs affect only cancer cells and do not affect other cells, and targeted drugs often work by blocking cancer cells from multiplying. Thus, the advantages of these targeted drugs, along with new developments, increase the demand for targeted therapies, which is expected to boost the market growth over the forecast period.
The targeting method and the highly effective tumor suppression effect expand the field of vision for the noninvasive diagnosis and treatment of oral cancer. The most important factor is that as the treatment ends, the side effects also go away. Also, because of resistance, targeted therapies work best when used with other therapies or with other treatment cancers such as chemotherapy. The advancement in the treatment option towards targeted therapy has boosted the growth of the segment during the forecast period.
North America is Expected to Dominate the Oral Cancer Market Over the Forecast Period
North America is expected to dominate the market owing to improved infrastructure of the health systems, including better health education and facilities. This has indirectly helped in earlier detection and availability of treatment options. According to the American Cancer Society, the estimated number of oral cancer patients in the United States is about 54,580 new cases in 2023. This shows the high burden of oral cancer in the country which likely increases the demand for oral cancer treatment products and is expected to boost the market growth over the study period in the region.
Most of the key pharmaceutical players have contributed to the market growth of the oral cancer market in North America through product recommendations, and launches. For instance, in November 2023, TerSera Therapeutics LLC stated that the National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recurrent, unresectable, or metastatic salivary gland tumors who were not eligible for surgery or radiation therapy. These recommendations increase the demand for usage of these drugs in the region which is likely to have a significant impact on the market over the forecast period.
Therefore, owing to the factors such as the high burden of oral cancers and new product recommendations the growth of the market studied is anticipated in the North American region.
Oral Cancer Therapy Industry Overview
The oral cancer market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of companies that hold significant market shares, and some key players are Bristol-Myers Squibb, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd.
Oral Cancer Therapy Market Leaders
-
Bristol Myers Squibb
-
Eli Lilly and Company
-
F. Hoffmann-La Roche Ltd
-
Teva Pharmaceutical Industries Ltd.
-
Merck & Co., Inc
*Disclaimer: Major Players sorted in no particular order
Oral Cancer Therapy Market News
- January 2023: Alkermes plc stated that nemvaleukin alfa (nemvaleukin), the company's investigational, engineered interleukin-2 (IL-2) variant immunotherapy, was granted an innovation passport for the treatment of mucosal melanoma under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA).
- September 2022: clinical researchers at the VA Greater Los Angeles Healthcare System collaborated with the Sylvester Comprehensive Cancer Centre at the University of Miami Miller School of Medicine. They began a phase-2 clinical trial for a naturally derived drug lozenge showing promising results and safety in combating oral cancer.
Oral Cancer Therapy Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in Tobacco Usage and Increasing Smoking Habits
- 4.2.2 Growing Oral Cancer Patient Population and Unmet Needs
- 4.2.3 Need for Early Treatment of the Oral Cancer
-
4.3 Market Restraints
- 4.3.1 Lack of Awareness Among General Public
- 4.3.2 Adverse Effects Associated with the Treatments
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Therapy Type
- 5.1.1 Chemotherapy
- 5.1.2 Targeted Drug Therapy
- 5.1.3 Radiation Type
- 5.1.4 Immunotherapy
- 5.1.5 Other Therapy Types
-
5.2 By Administration Type
- 5.2.1 Oral
- 5.2.2 Injectable
- 5.2.3 Other Administration Types
-
5.3 By End-User
- 5.3.1 Hospitals
- 5.3.2 Cancer Centres
- 5.3.3 Research Organizations
- 5.3.4 Other End-Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Bristol-Myers Squibb
- 6.1.2 Qilu Pharmaceutical Co., Ltd.
- 6.1.3 Teva Pharmaceutical Industries Ltd.
- 6.1.4 Eli Lilly And Company
- 6.1.5 F. Hoffmann-La Roche Ltd
- 6.1.6 Merck & Co., Inc
- 6.1.7 Novartis AG
- 6.1.8 Pfizer Inc
- 6.1.9 Fresenius Kabi AG
- 6.1.10 Sanofi
- 6.1.11 Takeda Pharmaceutical Company Limited
- 6.1.12 GSK plc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityOral Cancer Therapy Industry Segmentation
As per the scope of the report, oral cancer is a broad term for cancer that affects the mouth. There are various types of oral cancer, like lymphoma, mucosal melanoma, sarcomas, and others. The oral cancer market is segmented by therapy type (chemotherapy, targeted drug therapy, immunotherapy, radiation therapy, and other types), end-users (hospitals, cancer centers, research organizations, and other end-users), administration type (oral, injectable, and other administration types), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Therapy Type | Chemotherapy | |
| Targeted Drug Therapy | ||
| Radiation Type | ||
| Immunotherapy | ||
| Other Therapy Types | ||
| By Administration Type | Oral | |
| Injectable | ||
| Other Administration Types | ||
| By End-User | Hospitals | |
| Cancer Centres | ||
| Research Organizations | ||
| Other End-Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Oral Cancer Therapy Market Research FAQs
How big is the Oral Cancer Therapy Market?
The Oral Cancer Therapy Market size is expected to reach USD 2.05 billion in 2024 and grow at a CAGR of 5.32% to reach USD 2.65 billion by 2028.
What is the current Oral Cancer Therapy Market size?
In 2024, the Oral Cancer Therapy Market size is expected to reach USD 2.05 billion.
Who are the key players in Oral Cancer Therapy Market?
Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd. and Merck & Co., Inc are the major companies operating in the Oral Cancer Therapy Market.
Which is the fastest growing region in Oral Cancer Therapy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Oral Cancer Therapy Market?
In 2023, the North America accounts for the largest market share in Oral Cancer Therapy Market.
What years does this Oral Cancer Therapy Market cover, and what was the market size in 2023?
In 2023, the Oral Cancer Therapy Market size was estimated at USD 1.94 billion. The report covers the Oral Cancer Therapy Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Oral Cancer Therapy Market size for years: 2024, 2025, 2026, 2027 and 2028.
Oral Cancer Therapy Industry Report
Statistics for the 2024 Oral Cancer Therapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Oral Cancer Therapy analysis includes a market forecast outlook to for 2024 to (2024to2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
